InspireMD Receives Nasdaq Delisting Notice After Stock Falls Below $1.00

summarizeSummary

InspireMD received a Nasdaq delisting notice on July 17, 2026, after its stock traded below $1.00 for 30 consecutive days. The company has until January 13, 2027, to regain compliance, likely requiring a sustained price recovery or a reverse stock split.

check_boxKey Events · Legal and Risk Events · NSPR

• Nasdaq Delisting Notice Received

  On July 17, 2026, InspireMD was notified by Nasdaq that its common stock failed to maintain a minimum bid price of $1.00 per share for 30 consecutive business days, triggering non-compliance with Listing Rule 5550(a)(2).

• 180-Day Compliance Period

  The company has until January 13, 2027, to regain compliance by achieving a closing bid price of at least $1.00 for a minimum of 10 consecutive business days. Failure could lead to delisting, though a second 180-day period may be available if certain conditions are met.

• Reverse Stock Split Considered

  InspireMD stated it may effect a reverse stock split to cure the deficiency, a common but dilutive measure that would reduce the number of outstanding shares to artificially raise the per-share price.

• Existing Financial Distress Amplifies Risk

  The delisting notice compounds existing challenges: a going-concern warning, a product recall, and a $75 million ATM program that has already diluted shareholders. The stock currently trades at $0.69, well below the $1.00 threshold.

auto_awesomeAnalysis · NSPR · Industrial Applications And Services

InspireMD has been formally notified by Nasdaq that its stock no longer meets the $1.00 minimum bid price requirement, based on 30 consecutive trading days below that threshold. The company now has 180 days, until January 13, 2027, to regain compliance — typically by sustaining a closing price at or above $1.00 for at least 10 consecutive business days. If it fails, it may be eligible for a second 180-day period, but only if it meets other listing standards and notifies Nasdaq of its intent to cure, potentially through a reverse stock split. This notice arrives against a backdrop of existing going-concern warnings, a recent product recall, and a $75 million at-the-market offering program that has already pressured the stock. While the notice itself does not immediately delist the shares, it raises the risk of a forced move to the OTC market, which would reduce liquidity and investor access. The company's ability to regain compliance without a reverse split is uncertain given its current share price of $0.69.